真核细胞起始因子5A2是乳腺癌中的一种新型化疗耐药基因。
EIF5A2 is a novel chemoresistance gene in breast cancer.
作者信息
Liu Yu, Du Feiya, Chen Wei, Yao Minya, Lv Kezhen, Fu Peifen
机构信息
Breast Center of the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
出版信息
Breast Cancer. 2015 Nov;22(6):602-7. doi: 10.1007/s12282-014-0526-2. Epub 2014 Mar 18.
BACKGROUND
The eIF5A2 gene (encoding the eukaryotic initiation factor 5A2) located at 3q26 is a putative oncogene that is overexpressed in colon and rectal carcinomas, lung cancer and hepatocellular carcinoma. EIF5A2 overexpression correlates significantly with tumor metastasis and is an adverse prognostic marker. However, eIF-5A2 overexpression in breast cancer and its effect on chemotherapy are unknown.
METHODS
We measured eIF-5A2 expression and doxorubicin sensitivity in different human breast cancer cell lines (Bcap-1937, HCC1937, and MCF-7). To investigate a role for eIF-5A2 in chemoresistance, cells were treated with eIF-5A2-siRNA, exposed to various concentrations of doxorubicin, and toxicity was assayed by CCK-8 (cell counting kit).
RESULTS
The eIF-5A2 expression levels varied among breast cancer cells. Higher expression levels correlated with decreased doxorubicin sensitivity. Silencing of eIF-5A2 significantly improved doxorubicin toxicity in all three breast cancer cell lines.
CONCLUSION
This study shows that eIF-5A2 plays an important role in doxorubicin chemoresistance in breast cancer cells.
背景
位于3q26的eIF5A2基因（编码真核生物起始因子5A2）是一种推定的癌基因，在结肠癌、直肠癌、肺癌和肝细胞癌中过表达。EIF5A2过表达与肿瘤转移显著相关，是一种不良预后标志物。然而，eIF-5A2在乳腺癌中的过表达及其对化疗的影响尚不清楚。
方法
我们检测了不同人乳腺癌细胞系（Bcap-1937、HCC1937和MCF-7）中eIF-5A2的表达及对阿霉素的敏感性。为了研究eIF-5A2在化疗耐药中的作用，用eIF-5A2-siRNA处理细胞，使其暴露于不同浓度的阿霉素中，并用CCK-8（细胞计数试剂盒）检测毒性。
结果
乳腺癌细胞中eIF-5A2的表达水平各不相同。较高的表达水平与阿霉素敏感性降低相关。在所有三种乳腺癌细胞系中，沉默eIF-5A2均显著提高了阿霉素的毒性。
结论
本研究表明，eIF-5A2在乳腺癌细胞对阿霉素的化疗耐药中起重要作用。
Zotero 插件